Clinical trials: Measles Infection
Immunogenicity, Reactogenicity
Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
Open-label, single-arm trial, Primary Objectives included: 1. To assess the immunogenicity of TrivivacTM administered in healthy infants aged between 9-14 months. 2.
- Trial name
- NCT01763268
- Testing
- Trivivac vaccine
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Queen Sirikit National Institute of Child Health
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
The purpose of this study is to determine immune system function following vaccination in HIV-infected children currently taking anti-HIV drugs.
- Trial name
- NCT00257127
- Testing
- Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hand, Foot and Mouth Disease (HFMD)
The Phase IVd of Inactivated Enterovirus 71 Vaccine
Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae.
- Trial name
- NCT03296410
- Testing
- EV71 and two measles attenuated live vaccine, EV71 and attenuated Japanese encephalitis vaccine, two measles attenuated live vaccine
- Where
- China
- Volunteers
- 1,220 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Measles
Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
This study will be an epidemiological inquiry, in communicating confirmed measles cases. The contacts of the index cases will be asked about the measles diagnosis and previous measles vaccination, and will have their vaccination…
- Trial name
- NCT05592756
- Where
- Brazil
- Volunteers
- 2,964 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Measles
Measles Vaccination Cash Incentives Experimental Evidence From Nigeria
IDinsight is conducting a randomized controlled trial to assess the impact of various sized cash incentives for caretakers of infants that require a 9-month measles vaccination on the completion rate for the vaccine in Nigeria.
- Trial name
- NCT04013516
- Testing
- Cash Incentive, Call
- Where
- Nigeria
- Volunteers
- 1,088 people, healthy volunteers welcome
- Sponsor
- IDinsight
Measles
mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau
The question that this project seeks to answer, is whether mobile phones can be used to increase the measles vaccination coverage and timeliness in Guinea-Bissau.
- Trial name
- mimi (NCT02662595)
- Testing
- SMS reminder message, Voice call + SMS message
- Where
- 3 sites in Guinea-Bissau
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Measles, Mumps
Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
It is a clinicaltrial Phase III , randomized, double -blind , 4-arm (390 each one): This study will include 1560 children and will use 3 batches of vaccine produced by Bio - Manguinhos with viral bulk of GSK combined measles …
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT01991899
- Testing
- MMR Bio-Manguinhos, MMR GlaxoSmithKline
- Where
- Brazil
- Volunteers
- 1,560 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Measles
Long-term Follow-up of Measles Antibodies
Few data exist on long-term persistence of measles antibodies after vaccination of West African infants. The data that do exist indicate that the antibody titres decline very rapidly.
- Trial name
- NCT00168571
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 1,960 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
MEASLES DISEASE
Randomized Controlled Trial of Measles Vaccination Schedule
Measles is a preventable infectious viral disease. Since 1985, India has been administering a single dose of measles vaccine to all infants at 9 months of age.
- Trial name
- NCT03170765
- Testing
- Measles vaccine
- Where
- India
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Measles
Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience
Measles, can be prevented and eliminated by vaccination, is a highly contagious viral disease that can lead to serious complications, disability, and death.
- Trial name
- NCT05614791
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
MEASLES DISEASE
Unravelling the Measles Paradox in Children
Measles is caused by measles virus (MeV). The disease is associated with lymphopenia and immune suppression, which is an important cause of measles-associated morbidity and mortality.
- Trial name
- MISIA-k (NCT06923631)
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Rubella, Measles
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \&…
- Conditions
- Rubella, Measles, Mumps
- Trial name
- NCT01702428
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 90 sites in United States, Estonia and 4 more
- Volunteers
- 5,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rubella, Mumps
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in the US.
- Conditions
- Rubella, Mumps, Measles
- Trial name
- NCT02058563
- Testing
- Priorix®, Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
- Where
- 17 sites in United States, Estonia and 1 more
- Volunteers
- 996 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
ProQuad® Intramuscular vs Subcutaneous
Primary objective: To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00402831
- Testing
- ProQuad®
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Infections
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers
- Trial name
- NCT00626327
- Testing
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Where
- 90 sites in United States
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Diphtheria
Immunology of Non-specific Effects of Vaccine
OBJECTIVES General: To investigate the immunological background for the non-specific effects of diphtheria-tetanus-pertussis (DTP) and measles vaccines on child mortality Specific: Examine the cytokine responses and possible…
- Conditions
- Measles, Diphtheria, Tetanus, Pertussis
- Trial name
- NCT00168545
- Testing
- Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Measles, Mumps
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on…
- Conditions
- Measles, Mumps, Rubella, Hepatitis A
- Trial name
- NCT00313950
- Testing
- Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company